Antiaggregant effect of indobufen (K3920) measured by the platelet aggregate filtration pressure test (PAFP).
The platelet aggregate filtration pressure test (PAFP) was used to study the aggregant activity of single doses of 200 mg indobufen, administered either orally or by i.v. injection. This double-blind study using placebo in a crossover design was conducted in twelve patients whose baseline aggregation values were high. The compound showed markedly different antiaggregant activity from placebo at the various observation times after administration. The two administration routes did not produce any significant differences. The PAFP test can be useful in identifying atherosclerotic patients with platelet hyperaggregation, and for clinical pharmacology studies with platelet antiaggregant drugs.